Medical Oncology最新文献

筛选
英文 中文
The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology. 分子生物标记物在复发性胶质母细胞瘤试验中的作用:对基因组驱动的肿瘤学试验现状的评估。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-11-06 DOI: 10.1007/s12032-024-02555-7
K P Ameya, Durairaj Sekar
{"title":"The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.","authors":"K P Ameya, Durairaj Sekar","doi":"10.1007/s12032-024-02555-7","DOIUrl":"https://doi.org/10.1007/s12032-024-02555-7","url":null,"abstract":"","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAP superfamily proteins in human: a new target for cancer therapy. 人类的 CAP 超家族蛋白:癌症治疗的新目标。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-11-05 DOI: 10.1007/s12032-024-02548-6
Shenao Zhou, Qianqian Zhang, Jiawei Xu, Ruiqi Xiang, Xiaoping Dong, Xi Zhou, Zhonghua Liu
{"title":"CAP superfamily proteins in human: a new target for cancer therapy.","authors":"Shenao Zhou, Qianqian Zhang, Jiawei Xu, Ruiqi Xiang, Xiaoping Dong, Xi Zhou, Zhonghua Liu","doi":"10.1007/s12032-024-02548-6","DOIUrl":"https://doi.org/10.1007/s12032-024-02548-6","url":null,"abstract":"<p><p>The CAP (Cysteine-rich secretory protein, Antigen 5, and Pathogenesis-related protein 1) superfamily proteins (CAP proteins) are found in all kingdoms of life. The cysteine-rich secreted proteins are prevalent in human organs and tissues and serve as critical signaling molecules within cells, regulating a wide range of biochemical processes in the human body. Due to their involvement in numerous biological processes, CAP proteins have recently attracted significant attention, particularly in the context of tumorigenesis and cancer therapy. This review summarizes the expression patterns and roles of CAP proteins in various cancers. Additionally, it analyzes the mechanisms by which CAP proteins affect cancer cell proliferation and survival, regulate epithelial-mesenchymal transition, influence drug resistance, and regulate epigenetics. The review reveals that CAP proteins play distinct roles in various signaling pathways, such as the MAPK, PI3K-Akt, and p53 pathways, which are crucial for tumor progression. Furthermore, this review summarizes the tumor-inhibiting function of CAP proteins and their potential as cancer biomarkers. These findings suggest that CAP proteins represent a promising new target for innovative cancer diagnosis and treatment.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the editor on "Targeted gene therapy for cancer: the impact of microRNA multipotentiality". 致编辑的信--"癌症的靶向基因治疗:microRNA 多态性的影响"。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-11-05 DOI: 10.1007/s12032-024-02550-y
K P Ameya, Durairaj Sekar
{"title":"Letter to the editor on \"Targeted gene therapy for cancer: the impact of microRNA multipotentiality\".","authors":"K P Ameya, Durairaj Sekar","doi":"10.1007/s12032-024-02550-y","DOIUrl":"https://doi.org/10.1007/s12032-024-02550-y","url":null,"abstract":"","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer. 细胞周期蛋白 D3 蛋白降解受损是 HER2 阳性乳腺癌产生曲妥珠单抗耐药性的原因之一。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-11-02 DOI: 10.1007/s12032-024-02535-x
Zhuo Wang, Haiqi Lu, Yiming Zhong, Lifeng Feng, Hongchuan Jin, Xian Wang
{"title":"Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.","authors":"Zhuo Wang, Haiqi Lu, Yiming Zhong, Lifeng Feng, Hongchuan Jin, Xian Wang","doi":"10.1007/s12032-024-02535-x","DOIUrl":"10.1007/s12032-024-02535-x","url":null,"abstract":"<p><p>As the first anti-HER2 targeted agent approved by FDA in 1998, Trastuzumab has significantly improved the outcome of patients with HER2 positive metastatic breast cancer. Unfortunately, resistance to trastuzumab is a severe obstacle to its therapeutic efficacy in clinical application, and its mechanism has not yet been fully elucidated. In our study, we found that stabilization of cyclin D3 could be one reason for trastuzumab resistance. Trastuzumab could induce G1/G0 phase arrest by downregulating cyclin D3 protein expression. However, the protein expression of cyclin D3 was not affected in trastuzumab-resistant cells, which might be related to aberrant activation of ERK signaling pathway. Furthermore, degradation of cyclin D3 protein by trastuzumab was mainly resulted from ubiquitin-dependent proteasome mechanism instead of transcriptional regulation. In trastuzumab-resistant breast cancer cells, trastuzumab-induced degradation of cyclin D3 protein was abrogated. When the ubiquitin pathway was inhibited, cells would show a predisposition to resistance to trastuzumab. Further, CDK4/6 inhibitor can inhibit the proliferation of trastuzumab-resistant HER-2 positive breast cancer cells. Therefore, combination of CDK4/6 inhibitors and anti-HER2 targeted therapy may be an alternative and promising strategy to overcome trastuzumab resistance in the future.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete decongestive therapy phase 1: an expert consensus document. 完全去充血疗法第一阶段:专家共识文件。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-11-02 DOI: 10.1007/s12032-024-02407-4
Shelley DiCecco, Claire C Davies, Laura Gilchrist, Kim Levenhagen, Marie-Eve Letellier, Amy Rivera, Jan Weiss, Guenter Klose, Linda Hodgkins, Elizabeth Anderson, Andrea Cheville, Keith Moore, Linda Koehler
{"title":"Complete decongestive therapy phase 1: an expert consensus document.","authors":"Shelley DiCecco, Claire C Davies, Laura Gilchrist, Kim Levenhagen, Marie-Eve Letellier, Amy Rivera, Jan Weiss, Guenter Klose, Linda Hodgkins, Elizabeth Anderson, Andrea Cheville, Keith Moore, Linda Koehler","doi":"10.1007/s12032-024-02407-4","DOIUrl":"https://doi.org/10.1007/s12032-024-02407-4","url":null,"abstract":"<p><p>This document was drafted by interdisciplinary experts informed by the evidence and guided by their extensive lymphedema clinical experience at the 2023 American Cancer Society (ACS) Lymphedema Summit: Forward Momentum: Future Steps in Lymphedema Management hosted by the ACS, Lymphology Association of North America, and the Washington School of Medicine  in St. Louis, Missouri. Consensus statements were derived from a facilitated workshop and multiple follow-up discussions and meetings combining available evidence and clinical expertise. The consensus statements find that the essential components of complete decongestive therapy (CDT) are examination, compression, manual techniques (this may include but is not limited to manual lymph drainage), exercise, skin care, education, and self-management. Adjunctive interventions and alternatives may complement CDT. CDT should be provided by specifically trained healthcare practitioners in lymphedema management, preferably a certified lymphedema therapist. The individual's lymphedema etiology and presentation, comorbidities, and other pertinent clinical information will determine the components of CDT applied and the frequency and duration of care.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery. 利用纳米细胞内给药技术,靶向治疗胶质母细胞瘤中无法治愈的疾病。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-10-29 DOI: 10.1007/s12032-024-02546-8
Sakine Shirvalilou, Samideh Khoei, Reza Afzalipour, Habib Ghaznavi, Milad Shirvaliloo, Zahra Derakhti, Roghayeh Sheervalilou
{"title":"Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery.","authors":"Sakine Shirvalilou, Samideh Khoei, Reza Afzalipour, Habib Ghaznavi, Milad Shirvaliloo, Zahra Derakhti, Roghayeh Sheervalilou","doi":"10.1007/s12032-024-02546-8","DOIUrl":"https://doi.org/10.1007/s12032-024-02546-8","url":null,"abstract":"<p><p>Glioblastoma (GBM) is a highly prevalent and aggressive brain tumor in adults with limited treatment response, leading to a 5-year survival rate of less than 5%. Standard therapies, including surgery, radiation, and chemotherapy, often fall short due to the tumor's location, hypoxic conditions, and the challenge of complete removal. Moreover, brain metastases from cancers such as breast and melanoma carry similarly poor prognoses. Recent advancements in nanomedicine offer promising solutions for targeted GBM therapies, with nanoparticles (NPs) capable of delivering chemotherapy drugs or radiation sensitizers across the blood-brain barrier (BBB) to specific tumor sites. Leveraging the enhanced permeability and retention effect, NPs can preferentially accumulate in tumor tissues, where compromised BBB regions enhance delivery efficiency. By modifying NP characteristics such as size, shape, and surface charge, researchers have improved circulation times and cellular uptake, enhancing therapeutic efficacy. Recent studies show that combining photothermal therapy with magnetic hyperthermia using AuNPs and magnetic NPs induces ROS-dependent apoptosis and immunogenic cell death providing dual-targeted, immune-activating approaches. This review discusses the latest NP-based drug delivery strategies, including gene therapy, receptor-mediated transport, and multi-modal approaches like photothermal-magnetic hyperthermia combinations, all aimed at optimizing therapeutic outcomes for GBM.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma. 线粒体表观遗传学途径和天然化合物:抗击肝细胞癌的双重方法。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-10-27 DOI: 10.1007/s12032-024-02538-8
Abdulrahman Hatawsh, Roya Hadi Al-Haddad, Ukamaka Gladys Okafor, Lamis M Diab, Nino Dekanoidze, Adeniyi Ayinde Abdulwahab, Osama A Mohammed, Ahmed S Doghish, Rewan Moussa, Hanan Elimam
{"title":"Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.","authors":"Abdulrahman Hatawsh, Roya Hadi Al-Haddad, Ukamaka Gladys Okafor, Lamis M Diab, Nino Dekanoidze, Adeniyi Ayinde Abdulwahab, Osama A Mohammed, Ahmed S Doghish, Rewan Moussa, Hanan Elimam","doi":"10.1007/s12032-024-02538-8","DOIUrl":"https://doi.org/10.1007/s12032-024-02538-8","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading liver cancer that significantly impacts global life expectancy and remains challenging to treat due to often late diagnoses. Despite advances in treatment, the prognosis is still poor, especially in advanced stages. Studies have pointed out that investigations into the molecular mechanisms underlying HCC, including mitochondrial dysfunction and epigenetic regulators, are potentially important targets for diagnosis and therapy. Mitoepigenetics, or the epigenetic modifications of mitochondrial DNA, have drawn wide attention for their role in HCC progression. Besides, molecular biomarkers such as mitochondrial DNA alterations and non-coding RNAs showed early diagnosis and prognosis potential. Additionally, natural compounds like alkaloids, resveratrol, curcumin, and flavonoids show promise in HCC show promise in modulating mitochondrial and epigenetic pathways involved in cancer-related processes. This review discusses how mitochondrial dysfunction and epigenetic modifications, especially mitoepigenetics, influence HCC and delves into the potential of natural products as new adjuvant treatments against HCC.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives. 了解三阴性乳腺癌抗体-药物共轭物的化学和药理学,特别是依沙替康衍生物。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-10-26 DOI: 10.1007/s12032-024-02542-y
Sanjana Sawant, Gaurav Gopal Naik, Alakh N Sahu, Vijay A Jagtap
{"title":"Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives.","authors":"Sanjana Sawant, Gaurav Gopal Naik, Alakh N Sahu, Vijay A Jagtap","doi":"10.1007/s12032-024-02542-y","DOIUrl":"https://doi.org/10.1007/s12032-024-02542-y","url":null,"abstract":"<p><p>In the spectrum of breast malignancies, triple-negative breast cancer is the most widely spreading subtype of breast cancer due to a low availability of therapeutic remedies. Recently, antibody-drug conjugates dramatically resolved the landscape for the treatment of triple-negative breast cancer. This review mainly focuses on the chemistry, structure, mechanism of action, and role of antibody-drug conjugates in triple-negative breast cancer. Datopotecan Deruxtecan (Dato-DXd) is a new-generation ADC showing encouraging results for TNBC. In this review, we have also emphasized TROP-2-directed Datopotamab deruxtecan ADCs to treat triple-negative breast cancer, its synthesis, mechanism of action, pharmacokinetics, pharmacodynamics, adverse events, and their ongoing clinical trials.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma. 瘤内微生物群:诊断和治疗肝细胞癌的新兴力量。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-10-25 DOI: 10.1007/s12032-024-02545-9
Huanxiang Liu, Jiahao Zhang, Yuye Rao, Shengjie Jin, Chi Zhang, Dousheng Bai
{"title":"Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma.","authors":"Huanxiang Liu, Jiahao Zhang, Yuye Rao, Shengjie Jin, Chi Zhang, Dousheng Bai","doi":"10.1007/s12032-024-02545-9","DOIUrl":"https://doi.org/10.1007/s12032-024-02545-9","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) ranks among the most prevalent types of cancer in the world and its incidence and mortality are increasing year by year, frequently diagnosed at an advanced stage. Traditional treatments such as surgery, chemotherapy, and radiotherapy have limited efficacy, so new diagnostic and treatment strategies are urgently needed. Recent research has discovered that intratumoral microbiota significantly influences the development, progression, and metastasis of HCC by modulating inflammation, immune responses, and cellular signaling pathways. Intratumoral microbiota contributes to the pathologic process of HCC by influencing the tumor microenvironment and altering the function of immune system. This article reviews the mechanism of intratumoral microbiota in HCC and anticipates the future possibilities of intratumoral microbiota-based therapeutic strategies for HCC management. This emerging field provides fresh insights into early diagnosis and personalized approaches for HCC while holding substantial clinical application potential to improve patient outcomes and tailor interventions to individual tumor profiles.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-assembled nanoparticles of alginate and paclitaxel-triphenylphosphonium for mitochondrial apoptosis targeting. 用于线粒体凋亡靶向的海藻酸盐和紫杉醇-三苯基膦自组装纳米颗粒。
IF 2.8 4区 医学
Medical Oncology Pub Date : 2024-10-24 DOI: 10.1007/s12032-024-02540-0
Mehdi Esfandyari-Manesh, Bahar Morshedi, Parisa Joolaie, Rassoul Dinarvand
{"title":"Self-assembled nanoparticles of alginate and paclitaxel-triphenylphosphonium for mitochondrial apoptosis targeting.","authors":"Mehdi Esfandyari-Manesh, Bahar Morshedi, Parisa Joolaie, Rassoul Dinarvand","doi":"10.1007/s12032-024-02540-0","DOIUrl":"https://doi.org/10.1007/s12032-024-02540-0","url":null,"abstract":"<p><p>Paclitaxel (PTX), an antimitotic drug from the taxanes group, prevents the proliferation of breast cancer cells through mitosis arrest and activation by a cascade of signaling pathways that lead to apoptosis. Mitochondria is one of the important signaling routes for inducing apoptosis. For mitochondria targeting, triphenylphosphonium (TPP) with a delocalized charge and hydrophobic nature was utilized as a moiety to facilitate penetration through a phospholipid membrane of mitochondria. PTX-TPP was synthesized via pH-sensitive ester bond between hydroxyl groups of PTX and carboxylic acid of (4-carboxybutyl) TPP. Then PTX-TPP prodrug encapsulated in alginate nanoparticles, which were self-assembled by the ionotropic complexation technique for enhancement of mitochondrial apoptosis in breast cancer cells. The loading of PTX-TPP conjugation in self-assembled alginate nanoparticles was 16.5% and the particle size of nanoparticles was 123 nm with zeta potential around - 25.8 Mv. The in vitro cytotoxicity and IC50 of PTX-TPP nanoparticles in the growth of MCF7 cancer cell increased 6.3-fold higher than free PTX. The early apoptotic cells and the late apoptotic/necrotic cells for PTX-TPP nanoparticles were 11.6 and 3.9-fold higher than free PTX. This study indicated this mitochondrial-targeted self-assembled nanoparticles can inhibit the tumor cell growth of breast cancer.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信